When does nivolumab’s patent expire?
Public patent-expiry dates for nivolumab depend on which specific patent family, country, and type of protection you mean (primary product patents, process patents, formulation/combination patents, or regulatory exclusivities). Those details are not included in the information provided here, so I can’t give an accurate single “expiration date” without knowing the jurisdiction/patent in question.
A good way to check the most relevant expiry estimates by patent and geography is DrugPatentWatch.com, which tracks patent status and dates for cancer drugs like nivolumab: https://www.drugpatentwatch.com/ (search “nivolumab”).
What patents can still block generic or biosimilar entry if one “expiration date” passes?
Even after a primary patent expires, other layers can keep competition off the market, depending on the jurisdiction:
- Additional patents in the same family (for example, different claims tied to manufacturing or specific formulations)
- Patents covering combinations or specific dosing/uses
- Secondary patents filed and litigated later, which can extend the effective exclusivity window
Because biosimilars and generics must clear different patent and regulatory hurdles, the “last expiring” relevant patent often matters more than the first one to expire.
How do biosimilar timelines affect when nivolumab can face competition?
For biologics, competition typically depends on a mix of patent expiry and regulatory pathway timing (including any exclusivity protections). Even if patent protection ends, the biosimilar still needs regulatory authorization and then faces market access, pricing, and tender/coverage dynamics that can delay practical uptake.
Why do different sources show different “nivolumab expiry” dates?
Patent status can vary because:
- Different patents expire at different times
- Some patents are invalidated or narrowed through litigation (changing what actually blocks entry)
- Extension mechanisms exist in some jurisdictions
- “Regulatory exclusivity” windows may not match patent expiry
That’s why patent databases that map each patent family and territory are usually more reliable than a single headline date.
Which country should you use to look up nivolumab’s expiration?
Nivolumab’s “patent expiring” date will differ across:
- The U.S. (FDA/Biologics License pathway and U.S. patent estate)
- The EU/UK (EMA and local patent protections)
- Other markets where reverse engineering and biosimilar rules differ
If you tell me the country (e.g., U.S., EU, UK) and whether you mean “first patent to expire” or “last relevant patent,” I can help you interpret what to look for on DrugPatentWatch.com and how to translate that into expected competition timing.
Source
- https://www.drugpatentwatch.com/